Indivior Pharmaceuticals has delivered a 194.4% total return over the past five years, yet the stock still screens as attractively priced on Simply Wall St's valuation checks. That combination of strong long term performance and a high value score puts the current share price under closer scrutiny.

• Over five years, a 194.4% return signals that the market has already repriced Indivior Pharmaceuticals in a major way, so investors are now weighing how much further the story can run.
• The planned all stock merger with Supernus and expectations around SUBLOCADE's future demand can support the investment case, while the ongoing shareholder investigation into the merger terms may add an extra layer of perceived risk around execution and deal fairness.
• Indivior Pharmaceuticals passes 6 of 6 valuation checks, which suggests the broader assessment on Simply Wall St leans toward the stock still looking cheap on key metrics despite its past gains (6/6 value score).

The issue now is whether that combination of strong historical returns and a still supportive valuation score leaves enough upside to justify new money going into Indivior Pharmaceuticals at around US$39.01.

Does Indivior Pharmaceuticals Look Undervalued on Earnings?

The P/E ratio suits Indivior Pharmaceuticals because the company is already reporting earnings, so the share price can be compared directly with those profits. Indivior Pharmaceuticals currently trades on a P/E of about 12.9x, which sits below both the Pharmaceuticals industry average of roughly 16.9x and the peer group average of about 23.6x. That puts the stock at a lower earnings multiple than many listed drug makers.

The fair P/E ratio implied by Simply Wall St’s model for Indivior Pharmaceuticals is about 17.9x. That is higher than the current 12.9x, which indicates a sizeable gap between what investors are now paying for each dollar of earnings and what the model suggests could be reasonable given the company’s profile and risks. Despite the recent Supernus merger announcement and solid Q2 2026 earnings, the market is still pricing Indivior Pharmaceuticals at a discount to this tailored fair multiple.

On the P/E multiple, Indivior Pharmaceuticals stock currently appears undervalued relative to both its fair ratio and broader industry benchmarks.

The Indivior Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Indivior Pharmaceuticals give you a structured way to connect the valuation puzzle above with concrete scenarios for the company’s future. Each narrative spells out which combination of growth, margins and earnings would need to play out for Indivior Pharmaceuticals' stock to be worth clearly more or less than today’s price, and ties that view to a specific set of expectations. You can revisit those expectations as new information appears on the Community page.

One of the top community narratives on Indivior Pharmaceuticals: 26% undervalued

"The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026..."

Do you think there's more to the story for Indivior Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Indivior Pharmaceuticals screens as undervalued on its P/E multiple, both against peers and against the tailored fair ratio implied by Simply Wall St’s model. That gap suggests investors are still hesitant to pay up despite supportive earnings and the Supernus merger story. For you, the key question is whether current concerns around the merger process and execution risk are temporary, or whether they are exactly what the market is pricing in. The crux of the debate is whether that discount reflects a genuine opportunity or a value trap if SUBLOCADE demand or integration progress disappoints.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.